LYMPHOMA, MYELOMA AND GENOMICS
Professor Dipti Talaulikar
Senior Consultant in Clinical and Laboratory Haematologist,
Canberra Health Services, Australia &
ANU School of Medicine and Psychology, The Australian National University
Canberra, Australia
RESEARCHER PROFILE
Filmed in Canberra, Australia | November 2025
Professor Dipti Talaulikar is a clinical and laboratory haematologist with expertise in genomics, working at Canberra Health Services, and Professor at ANU. She has a clinical and research interest in lymphoma, myeloma and genomics, and has authored close to 100 peer reviewed papers, including several clinical guidelines that have had a significant impact on clinical practice.
Professor Talaulikar is an inclusive and innovative educator, having been involved with teaching medical students since the inception of the ANU Medical School, and has won 5 awards including the Vice Chancellor awards for teaching and education.
Her conviction, that knowledge has to be linked with community work, has led her to develop The Link program at ANU, with a focus on sharing knowledge across boundaries. She is passionate about gender equity and has developed the Link and Grow Mentoring Program for diverse women in health and medicine.
She is the President branch of ASMOF (Australian Salaried Medical Officers Federation) and the chair of the Gender Equity Group in Federal ASMOF.
Source: Supplied
https://orcid.org/0000-0001-6766-8345
-
Personalised approaches to lung therapy
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
-
Next Generation Condom Contraception, Dr David Shepherd
Dr David Shepherd is a Lead Production Engineer and Materials Specialist at Eudaemon Technologies. His journey began at the University of Wollongong, where he pursued advanced studies and eventually obtained a PhD under the guidance of a distinguished professor. His research initially focused on actuating materials and artificial muscles, particularly centred around hydrogel materials. These early explorations have seamlessly evolved into his current focus on utilising hydrogels in the realm of sexual reproductive health, with a specific emphasis on developing innovative hydrogel condoms.
-
Role of metabolic dysfunction in advanced prostate cancer
Dr Gunter was drawn to the area of prostate cancer research and the intersection between chronic metabolic disorders and their emerging relationship to cancer. Her strengths include expertise in the metabolic syndrome, insulin signalling and metabolism, and she has a demonstrated record of successful and productive research projects in metabolic research where she now applies her efforts to understanding the role of metabolic dysfunction in advanced prostate cancer.
